Welcome! Login | Register
 

Worcester Ranked Among Worst Places in U.S. to Retire—Worcester Ranked Among Worst Places in U.S. to…

Man Arrested After Breaking Into Orient Street Home in Worcester—Man Arrested After Breaking Into Orient Street Home…

MA Health Connector Launches 1st Phase of Small-Business Website—MA Health Connector Launches 1st Phase of Small-Business…

Newport Manners & Etiquette: Houseguest Dog + Gifts, Full Bar + Neglectful Dad—Newport Manners & Etiquette: Houseguest Dog + Gifts,…

Bravehearts Ranked 7th in Country for Attendance During 2017 Season—Bravehearts Ranked 7th in Country for Attendance During…

VNA Care Network Seeking Hospice Volunteers—VNA Care Network Seeking Hospice Volunteers

Red Sox Turn Triple Play, Score 8 Runs in 5th to Roll Cardinals 10-4—Red Sox Turn Triple Play, Score 8 Runs…

Chef Walter’s Flavors + Knowledge: Peppery Mussel Stew—Chef Walter's Flavors + Knowledge: Peppery Mussel Stew

Massachusetts Ranked Among Best States to Have a Baby—Massachusetts Ranked Among Best States to Have a…

Woman Arrested for OUI Following Serious Car Accident on Cambridge St.—Woman Arrested for OUI Following Serious Car Accident…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.

 

X

Stay Connected — Free
Daily Email